Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Cell Signal. 2021 Apr;80:109910. doi: 10.1016/j.cellsig.2020.109910. Epub 2020 Dec 30.
Colorectal cancer (CRC) is a noticeable reason of cancer-associated deaths with a high incidence and mortality rate. Countless effort have been put into the improving clinical management of CRC patients including more effective tools and a wide variety of biomarkers for diagnostic, prognostic or predictive purposes. In recent years, dysregulated miRNAs have been emerged as highly sensitive and specific markers to manage CRC in an effective way. They can play key roles in carcinogenesis as potential oncogenes, tumor suppressors or regulators of cancer network. Therefore, miRNAs may serve as molecular tools that can be quantified and used in diagnostic and prognostic approaches. Growing evidence also suggests that forced expression of tumor suppressor miRNAs or inhibiting the oncogene ones, can be used as a novel treatment strategy. In this review, we focus on the clinical applications of miRNAs as promising biomarkers of early cancer detection, prognosis and treatment.
结直肠癌（CRC）是癌症相关死亡的一个显著原因，具有较高的发病率和死亡率。为了改善 CRC 患者的临床管理，人们付出了无数努力，包括更有效的工具和各种用于诊断、预后或预测目的的生物标志物。近年来，失调的 miRNA 已成为一种有效的 CRC 管理方法，其作为高度敏感和特异的标志物被广泛研究。它们可以作为潜在的癌基因、肿瘤抑制因子或癌症网络调节剂，在肿瘤发生中发挥关键作用。因此，miRNA 可以作为分子工具进行定量，并用于诊断和预后方法。越来越多的证据表明，强制表达肿瘤抑制 miRNA 或抑制癌基因 miRNA，可作为一种新的治疗策略。在这篇综述中，我们重点关注 miRNA 作为早期癌症检测、预后和治疗有前途的生物标志物的临床应用。
